

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

This document includes particulars given in compliance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "Rules") and is published for the purpose of giving information with regard to us and obtaining a listing of the Warrants on the Stock Exchange. We accept full responsibility for the accuracy of the information contained in the Listing Documents (as defined below) and confirm, having made all reasonable enquiries, that to the best of our knowledge and belief there are no other facts the omission of which would make any statement in such Listing Documents misleading.

**Investors are warned that the price of the Warrants may fall in value as rapidly as it may rise and holders may sustain a total loss of their investment. Prospective purchasers should therefore ensure that they understand the nature of the Warrants and carefully study the risk factors set out in this document and, where necessary, seek professional advice, before they invest in the Warrants.**

The Warrants constitute our general unsecured contractual obligations and of no other person and will rank equally among themselves and with all our other unsecured obligations (save for those obligations preferred by law) upon liquidation. If you purchase the Warrants, you are relying upon our creditworthiness and have no rights under the Warrants against the Company.

## Supplemental Listing Document for Warrants

issued by



**UBS AG**

*(incorporated with limited liability in Switzerland)*

acting through its **London Branch**

**Sponsor**

**UBS SECURITIES ASIA LIMITED**

### Key terms

Warrants	
<b>Stock code</b>	18467
<b>Issue size</b>	200,000,000 Warrants
<b>Style</b>	European style cash settled
<b>Type</b>	Call
<b>Company</b>	China Construction Bank Corporation
<b>Shares</b>	Existing issued ordinary H shares of RMB 1.00 each
<b>Board Lot</b>	1,000 Warrants
<b>Issue Price per Warrant</b>	HKD 0.250
<b>Exercise Price</b>	HKD 6.000
<b>Cash Settlement Amount per Board Lot (if any) payable at expiry</b>	$\frac{\text{Entitlement} \times (\text{Average Price} - \text{Exercise Price}) \times \text{one Board Lot}}{\text{Number of Warrant(s) per Entitlement}}$
<b>Average Price</b>	The arithmetic mean of the closing price of one Share for each of the 5 Valuation Dates subject to our right to determine the closing price in good faith in certain circumstances upon the occurrence of a Market Disruption Event (as defined in the Conditions), as described further in Condition 2(C)
<b>Entitlement</b>	1 Share
<b>Number of Warrant(s) per Entitlement</b>	1 Warrant
<b>Maximum number of Shares to which the Warrants relate</b>	200,000,000 Shares
<b>Launch Date</b>	11 May 2012
<b>Issue Date</b>	17 May 2012
<b>Listing date*</b>	Expected to be 18 May 2012 ("Dealing Commencement Date")
<b>Valuation Date</b>	Each of the five Business Days immediately preceding the Expiry Date subject to any potential postponement upon the occurrence of a Market Disruption Event, provided that no Valuation Date can fall on or after the Expiry Date. Please refer to Condition 2(C) for details.
<b>Expiry Date*</b>	19 November 2012

\* If such day is not a Business Day in Hong Kong, the immediately succeeding Business Day.

You must read the above together with our base listing document dated 10 April 2012 (as supplemented by any addenda to be issued from time to time), in particular, Part A entitled “Terms and Conditions of Cash Settled Warrants over Single Equities” set out in Appendix 1 of our base listing document (“**Conditions**”).

## IMPORTANT INFORMATION

**The Warrants are structured products which involve derivatives. Do not invest in them unless you fully understand and are willing to assume the risks associated with them.**

### What is this document about?

This document is for information purposes only and does not constitute an offer, an advertisement or invitation to the public to subscribe for or to acquire the Warrants. It is possible that there may have been dealings in the Warrants since the Launch Date.

### What documents should I read before investing in the Warrants?

You must read this document together with our base listing document dated 10 April 2012 (as supplemented by any addenda to be issued from time to time) (together, the “**Listing Documents**”). The Listing Documents are accurate as at the date of this document. You should carefully study the risk factors set out in the Listing Documents.

### What are our credit ratings?

Our long term debt ratings are:

Rating agency	Rating as of the Launch Date
Moody's Investors Service, Inc., New York	Aa3
Standard and Poor's Ratings Services, a division of the McGraw-Hill Companies Inc	A
Fitch Ratings Ltd., London	A

Rating agencies usually receive a fee from the issuers that they rate.

When evaluating our creditworthiness, you should not solely rely on our credit ratings because:

- a credit rating is not a recommendation to buy, sell or hold the Warrants;
- ratings of issuers may involve difficult-to-quantify factors such as market competition, the success or failure of new products and markets and managerial competence; and
- a high credit rating is not necessarily indicative of low risk. Our credit ratings as of the Launch Date are for reference only. Any downgrading of our ratings could result in a reduction in the value of the Warrants.

### The Warrants are not rated.

### Are we regulated by any bodies referred to in Rule 15A.13(2) or (3)?

We are a licensed bank regulated by the Hong Kong Monetary Authority. We are also regulated by, among others, the Swiss Financial Market Supervisory Authority and the Financial Services Authority of United Kingdom.

### Are we subject to any litigation?

Save as disclosed in the Listing Documents, we and our subsidiaries are not aware of any litigation or claims of material importance pending or threatened against us or them.

### Authorisation of the Warrants

The issue of the Warrants was authorised by our board of directors on 19 September 2001.

### Has our financial position changed since last financial year-end?

There has been no material adverse change in our financial or trading position since 31 December 2011.

### Do I need to pay any transaction cost?

The Stock Exchange charges a trading fee of 0.005 per cent. and the Securities and Futures Commission charges a transaction levy of 0.003 per cent in respect of each transaction effected on the Stock Exchange payable by each of the seller and the buyer and calculated on the value of the consideration for the Warrants. The levy for the investor compensation fund is currently suspended. You do not need to pay any stamp duty in respect of the Warrants.

### Where can I inspect the relevant documents?

The following documents are available for inspection during usual business hours on any weekday (Saturdays, Sundays and holidays excepted) until the Expiry Date at the offices of UBS Securities Asia Limited:

- our 2011 annual report for the period ended 31 December 2011 and our first quarter 2012 financial report for the quarterly period ended 31 March 2012;
- consent letter of the Auditors;
- each of the Listing Documents (in separate English and Chinese versions); and
- the instrument executed by us on 10 April 2006.

The Listing Documents are also available on the website of the Stock Exchange at [www.hkex.com.hk](http://www.hkex.com.hk).

各上市文件亦可於聯交所網站([www.hkex.com.hk](http://www.hkex.com.hk)) 瀏覽。

### Have the auditors consented to the inclusion of their report to the Listing Documents?

Our auditors (“**Auditors**”) have given and have not withdrawn their written consent to the inclusion of their report dated 13 March 2012 and/or the references to their name in our base listing document, in the form and context in which they are included. Their report was not prepared exclusively for incorporation into our base listing document. The Auditors do not have our shares or shares in our subsidiaries, nor do they have the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities or securities of any of its subsidiaries.

### Selling restrictions

The Warrants have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and will not be offered, sold, delivered or traded, at any time, indirectly or directly, in the United States or to, or for the account or benefit of, any U.S. person (as defined in the Securities Act).

The offer or transfer of the Warrants is also subject to the selling restrictions specified in our base listing document.

### How can I get information about UBS AG?

You may visit [www.ubs.com](http://www.ubs.com) to obtain information about us. You must read the section headed “Additional information relating to us” which contains further information relating to us after the date of our base listing document. That section supplements the information set out in our base listing document.

### Capitalised terms and inconsistency

Unless otherwise specified, capitalised terms used in this document have the meanings set out in the Conditions. Terms used in this document apply to the Warrants described on the cover page.

If this document is inconsistent with our base listing document, this document prevails.

## OVERVIEW OF WARRANTS

### What is a derivative warrant?

A derivative warrant is an instrument which gives the holder a right to “buy” or “sell” an underlying asset at a pre-set price called the exercise price on the expiry date. Investing in the warrants does not give you a right in the underlying asset.

Derivative warrants usually cost a fraction of the price of the underlying asset and may provide leveraged return to you (but conversely, it could also magnify your losses).

### How and when can I get back my investment?

The Warrants are European style cash settled derivative warrants linked to the Shares. European style warrants can only be exercised on the expiry date. The Warrants will be automatically exercised on the Expiry Date, entitling the holder to a cash amount called the “**Cash Settlement Amount**” (if positive) according to the terms and conditions in the Listing Documents.

You will receive the Cash Settlement Amount less any Exercise Expenses at expiry. **If the Cash Settlement Amount is equal to or less than the Exercise Expenses, the Warrants will expire worthless on the Expiry Date.**

### How do the Warrants work?

The potential payoff at expiry for the Warrants is calculated by us by reference to the difference between the Exercise Price and the Average Price of the underlying Share.

A call Warrant is suitable for an investor holding a bullish view of the price of the underlying Share during the term of the Warrant.

A call Warrant will be exercised if the Average Price of the underlying Share is greater than its Exercise Price. The more the Average Price is above the Exercise Price, the higher the payoff at expiry. If the Average Price is at or below the Exercise Price, the investor in the call Warrant will lose all of his investment.

### What are the factors determining the price of a derivative warrant?

The price of a warrant generally depends on the price of the underlying share. However, throughout the term of the warrants, their price will be influenced by a number of factors, including:

- the price of the underlying share and the exercise price of the warrants;
- the volatility of the price of the underlying share (being a measure of the fluctuation in the price of the underlying share);
- the time remaining to expiry: generally, the longer the remaining life of the warrants, the greater its value;
- interest rates;
- expected dividend payments or other distributions (if any) on the underlying share;
- the supply and demand for the warrants; and
- our creditworthiness.

### What is my maximum loss?

The maximum loss in warrants will be limited to your investment amount plus any transaction cost.

### Can I sell the Warrants before maturity?

Yes. We have made an application for listing of, and permission to deal in, the Warrants on the Stock Exchange. All necessary arrangements have been made to enable the Warrants to be admitted into the Central Clearing and Settlement System (“**CCASS**”). Issue of the Warrants is conditional upon listing being granted. From the Dealing Commencement Date, you may sell or buy the Warrants on the Stock Exchange.

The Liquidity Provider will make a market in the Warrants by providing bid and/or sell prices. See the section headed “**Liquidity**” of this document for further information.

### How can I get information about the Shares?

You may obtain information on the Shares (including the Company’s financial reports) by visiting the Stock Exchange website at [www.hkex.com.hk](http://www.hkex.com.hk) or the Company’s website at:

Company	website
China Construction Bank Corporation	<a href="http://www.ccb.com">http://www.ccb.com</a>

### How can I get information about the Warrants after issue?

You may visit the Stock Exchange website at [www.hkex.com.hk](http://www.hkex.com.hk) to obtain information on the Warrants or any notice given by us or the Stock Exchange in relation to the Warrants.

We have included references to websites in this document to indicate how further information may be obtained.

Information appearing on those websites does not form part of the Listing Documents. You should conduct your own web searches to ensure that you are viewing the most up-to-date information.

## OTHER KEY TERMS, LIQUIDITY AND SETTLEMENT

You must read this summary together with our base listing document, in particular, the Conditions.

Summary of other key terms	
<b>Form of the Warrants</b>	The Warrants will be represented by a global certificate in the name of HKSCC Nominees Limited. We will not issue definitive certificates for the Warrants. You may arrange for your broker to hold the Warrants in a securities account on your behalf, or if you have a CCASS Investor Participant securities account, you may arrange for the Warrants to be held in such account. You will have to rely on the records of CCASS and/or the statements you receive from your brokers as evidence of your beneficial interest in the Warrants.

<b>Stock Exchange</b>	The Stock Exchange of Hong Kong Limited. No application has been made to list the Warrants on any other exchange.
-----------------------	---

Liquidity	
<b>Liquidity Provider</b>	Stock code: 18467 Name of Liquidity Provider: UBS Securities Hong Kong Limited Address: 52/F, Two International Finance Centre, 8 Finance Street, Central, Hong Kong Broker ID Number: 9563

The Liquidity Provider is our affiliate and is regulated by the Stock Exchange and the Securities and Futures Commission. It will act as our agent in providing quotes.

<b>Quotes</b>	You can request a quote by calling the Liquidity Provider at:  telephone number: + 852 2971 6628.  The Liquidity Provider will respond within ten minutes and the quote will be displayed on the Stock Exchange's designated stock page for the Warrants.
---------------	---

<b>Maximum spread between bid and offer prices</b>	25
--	----

<b>Factors for determining the bid and offer prices</b>	The Liquidity Provider will consider factors, including, without limitation, the prevailing market price of the Shares, the price volatility of the Shares, prevailing interest rates, the time left to the expiry of the Warrants, the dividend yield of the Shares and the Exercise Price of the Warrants.
---	--

<b>Minimum quantity for which liquidity will be provided</b>	10 Board Lots
--	---------------

<b>Circumstances under which the Liquidity Provider may not be able to, and shall not be obliged to, provide liquidity</b>	<ul style="list-style-type: none"><li>(i) during the first five minutes of each morning trading session or the first five minutes after trading commences for the first time on any trading day;</li><li>(ii) during a pre-opening session or a closing auction session (if applicable) or any other circumstances as may be prescribed by the Stock Exchange from time to time;</li><li>(iii) when the Warrants are suspended from trading for any reason;</li><li>(iv) when there are no Warrants available for market making, in which event, only a bid price will be available. Warrants held by us or any of our affiliates in a fiduciary or agency capacity are not Warrants available for market making;</li><li>(v) during the 5 Business Days immediately preceding the Expiry Date;</li><li>(vi) if there are operational and technical problems beyond the control of the Liquidity Provider hindering the ability of the Liquidity Provider to provide liquidity;</li><li>(vii) if the stock market experiences exceptional price movement and volatility;</li><li>(viii) if a Market Disruption Event occurs;</li><li>(ix) when the ability of the Liquidity Provider acting on our behalf to source a hedge or unwind an existing hedge is materially affected by the prevailing market condition; and</li><li>(x) if the theoretical value of the Warrants is less than HKD 0.01. If the Liquidity Provider chooses to provide liquidity under this circumstance, both bid and ask prices will be made available.</li></ul>
--	--

## Settlement

<b>Settlement date upon a transfer</b>	The Warrants may only be transferred in a Board Lot (or integral multiples thereof). Where a transfer of Warrants takes place on the Stock Exchange, settlement must currently be made not later than two trading days.
<b>Exercise</b>	The Warrants will be automatically exercised on the Expiry Date in integral multiples of the Board Lot if the Cash Settlement Amount is positive; otherwise, you will lose all of your investment. We will deliver the Cash Settlement Amount (if any) net of any Exercise Expenses to HKSCC Nominees Limited, which will then distribute such amount to the securities account of your broker or to your CCASS Investor Participant securities account (as the case may be).
<b>Exercise Expenses</b>	You are responsible for any Exercise Expenses. Exercise Expenses mean any charges or expenses including any taxes or duties which are incurred in respect of the exercise of the Warrants. If the Cash Settlement Amount is equal to or less than the Exercise Expenses, no amount is payable.
<b>Settlement Date upon automatic exercise at expiry</b>	Within 3 CCASS Settlement Days after the Expiry Date.

## RISK FACTORS

You must read these risk factors together with the risk factors set out in our base listing document.

### **Warrants may expire worthless**

Although the cost of a Warrant may cost a fraction of the value of the underlying Share, the Warrant's price may change more rapidly than the underlying Share.

Unlike stocks, the Warrants have a limited life and will expire at the Expiry Date. In the worst case, the Warrants may expire with no value. The Warrants are only suitable for experienced investors who have a positive view on the performance of the underlying Share during the term of the Warrants and are willing to accept the risk that they may lose all their investment.

### **The Warrants can be volatile**

Prices of the Warrants may rise or fall rapidly. You should carefully consider, among other things, the following factors before dealing in the Warrants:

- (i) the prevailing trading price of the Warrants;
- (ii) the value and volatility of the underlying Share;
- (iii) the time remaining to expiry;
- (iv) the probable range of the Cash Settlement Amount;
- (v) the interim interest rates and expected dividend payments on the underlying Share;
- (vi) the liquidity of the underlying Share;
- (vii) any related transaction cost; and
- (viii) our creditworthiness.

### **Time decay**

The value of a Warrant is likely to decrease over time. Therefore, the Warrants should not be viewed as products for long term investments.

### **There is no assurance that the value of the Warrants will correlate with movements of the underlying Share**

The value of the Warrants may not correspond with the movements in the underlying Share price. If you buy the Warrants with a view to hedge against your exposure to the underlying Share, it is possible that you could suffer loss in your investment in the underlying Share and the Warrants.

### **The Listing Documents are not the sole basis for making an investment decision**

The Listing Documents do not take into account your investment objectives, financial situation or particular needs. Nothing in the Listing Documents should be construed as a recommendation by us or our affiliates to invest in the Warrants or the underlying Share.

### **Possible limited secondary market**

The Liquidity Provider may be the only market participant for the Warrants and therefore the secondary market for the Warrants may be limited. The more limited the secondary market, the more difficult it may be for you to realise the value in the Warrants prior to expiry.

### **Adjustment related risk**

The occurrence of certain events (including, without limitation, a rights issue, bonus issue or cash distribution by the Company, a subdivision or consolidation of the Shares and a restructuring event of the Company) may entitle us to adjust the terms and conditions of the Warrants. However, we are not obliged to adjust the terms and conditions of the Warrants for every event that affects the underlying Share. Any adjustment or decision not to make any adjustment may adversely affect the value of the Warrants. Please refer to Condition 5 for details about adjustments.

### **Suspension of trading**

If trading in the underlying Share is suspended on the Stock Exchange, trading in the Warrants will be suspended for a similar period. In the case of a prolonged suspension period, the market price of the Warrants may be subject to a significant impact of time decay and may fluctuate significantly upon resumption of trading after such prolonged suspension period.

### **Possible early termination**

The Warrants will be terminated early in the event of liquidation of the Company.

### **Conflict of interest**

We and our subsidiaries and affiliates engage in a wide range of commercial and investment banking, brokerage, funds management, hedging, investment and other activities and may possess material information about the underlying Shares or issue or update research reports on the Shares. Such activities, information and/or research reports may involve or affect the Shares and may cause consequences adverse to you or otherwise create conflicts of interests in connection with the issue of the Warrants. We have no obligation to disclose such information and may issue research reports and engage in any such activities without regard to the issue of the Warrants.

In the ordinary course of our business, we and our subsidiaries and affiliates may effect transactions for our own account or for the account of our customers and may enter into one or more transactions with respect to the Shares or related derivatives. This may indirectly affect your interests.

### **Global registered form**

The Warrants are issued in global registered form and is held on your behalf within the Central Clearing and Settlement System. You will not receive any definitive certificate and your name will not be registered in the register of the Warrants. You will have to rely on your broker and the statements you receive from it as evidence of your interest in the Warrants.

## **ADDITIONAL INFORMATION RELATING TO US**

### **First Quarter 2012 Report**

We released our first quarter 2012 report for the quarterly period ended on 31 March 2012 on 2 May 2012. You may visit our website at [http://www.ubs.com/global/en/about\\_ubs/investor\\_relations/quarterly\\_reporting/2012.html](http://www.ubs.com/global/en/about_ubs/investor_relations/quarterly_reporting/2012.html) to access our first quarter 2012 report.

The information set out under this paragraph has been extracted without adjustment from our first quarter 2012 report. Page references under this paragraph refer to pages in such report.

# Interim consolidated financial statements (unaudited)

## Income statement

CHF million, except per share data	Note	For the quarter ended			% change from	
		31.3.12	31.12.11	31.3.11	4Q11	1Q11
Interest income	3	4,130	4,139	4,578	0	(10)
Interest expense	3	(2,539)	(2,395)	(2,796)	6	(9)
Net interest income	3	1,591	1,745	1,781	(9)	(11)
Credit loss (expense)/recovery		37	(14)	3		
Net interest income after credit loss expense		1,628	1,731	1,784	(6)	(9)
Net fee and commission income	4	3,843	3,560	4,240	8	(9)
Net trading income	3	961	443	2,203	117	(56)
Other income	5	93	128	117	(27)	(21)
Total operating income		6,525	5,862	8,344	11	(22)
Personnel expenses	6	3,643	3,501	4,407	4	(17)
General and administrative expenses	7	1,398	1,652	1,488	(15)	(6)
Depreciation of property and equipment		158	198	191	(20)	(17)
Amortization of intangible assets		23	29	24	(21)	(4)
Total operating expenses		5,221	5,381	6,110	(3)	(15)
Operating profit before tax		1,304	481	2,235	171	(42)
Tax expense/(benefit)	9	476	160	426	198	12
Net profit		828	321	1,809	158	(54)
Net profit attributable to non-controlling interests		1	2	2	(50)	(50)
<b>Net profit attributable to UBS shareholders</b>		<b>827</b>	<b>319</b>	<b>1,807</b>	<b>159</b>	<b>(54)</b>
<b>Earnings per share (CHF)</b>						
Basic earnings per share	8	0.22	0.09	0.48	144	(54)
Diluted earnings per share	8	0.22	0.08	0.47	175	(53)

## Statement of comprehensive income

CHF million	For the quarter ended				
		31.3.12		31.12.11	31.3.11
	Total	UBS share- holders	Non-controlling interests	Total	Total
<b>Net profit</b>	<b>828</b>	<b>827</b>	<b>1</b>	<b>321</b>	<b>1,809</b>
<b>Other comprehensive income</b>					
<b>Foreign currency translation</b>					
Foreign currency translation movements, before tax	(873)	(797)	(76)	784	(76)
Foreign exchange amounts reclassified to the income statement from equity	7	7		(3)	(2)
Income tax relating to foreign currency translation movements	68	68		(105)	0
Subtotal foreign currency translation movements, net of tax <sup>1</sup>	(798)	(722)	(76)	676	(78)
<b>Financial investments available-for-sale</b>					
Net unrealized gains/(losses) on financial investments available-for-sale, before tax	35	35		17	(118)
Impairment charges reclassified to the income statement from equity	29	29		3	4
Realized gains reclassified to the income statement from equity	(60)	(60)		(62)	(44)
Realized losses reclassified to the income statement from equity	6	6		2	18
Income tax relating to net unrealized gains/(losses) on financial investments available-for-sale	(2)	(2)		(3)	20
Subtotal net unrealized gains/(losses) on financial investments available-for-sale, net of tax <sup>1</sup>	8	8		(43)	(121)
<b>Cash flow hedges</b>					
Effective portion of changes in fair value of derivative instruments designated as cash flow hedges, before tax	(5)	(5)		670	(510)
Net (gains)/losses reclassified to the income statement from equity	(256)	(256)		(307)	(297)
Income tax effects relating to cash flow hedges	53	53		(78)	168
Subtotal changes in fair value of derivative instruments designated as cash flow hedges <sup>1</sup>	(209)	(209)		285	(639)
<b>Total other comprehensive income</b>	<b>(998)</b>	<b>(922)</b>	<b>(76)</b>	<b>918</b>	<b>(837)</b>
<b>Total comprehensive income</b>	<b>(170)</b>	<b>(95)</b>	<b>(75)</b>	<b>1,239</b>	<b>971</b>
Total comprehensive income attributable to non-controlling interests	(75)			(15)	106
<b>Total comprehensive income attributable to UBS shareholders</b>	<b>(95)</b>			<b>1,254</b>	<b>865</b>

<sup>1</sup> Other comprehensive income attributable to UBS shareholders related to foreign currency translations was positive CHF 693 million in the fourth quarter of 2011 and negative CHF 182 million in the first quarter of 2011. Other comprehensive income related to financial investments available-for-sale and cash flow hedges was attributable to UBS shareholders for all periods presented.

**Balance sheet**

<i>CHF million</i>	Note	31.3.12	31.12.11	% change from 31.12.11
<b>Assets</b>				
Cash and balances with central banks		82,865	40,638	104
Due from banks		30,484	23,218	31
Cash collateral on securities borrowed		49,724	58,763	(15)
Reverse repurchase agreements		182,397	213,501	(15)
Trading portfolio assets	10	187,978	181,525	4
<i>of which: assets pledged as collateral</i>		50,562	39,936	27
Positive replacement values	14	417,870	486,584	(14)
Cash collateral receivables on derivative instruments		35,256	41,322	(15)
Financial assets designated at fair value		8,830	10,336	(15)
Loans		265,922	266,604	0
Financial investments available-for-sale	11	59,795	53,174	12
Accrued income and prepaid expenses		6,334	6,327	0
Investments in associates		785	795	(1)
Property and equipment		5,751	5,688	1
Goodwill and intangible assets		9,345	9,695	(4)
Deferred tax assets		8,028	8,526	(6)
Other assets	15	14,473	12,465	16
<b>Total assets</b>		<b>1,365,837</b>	<b>1,419,162</b>	<b>(4)</b>
<b>Liabilities</b>				
Due to banks		31,647	30,201	5
Cash collateral on securities lent		7,954	8,136	(2)
Repurchase agreements		118,228	102,429	15
Trading portfolio liabilities	10	52,607	39,480	33
Negative replacement values	14	404,247	473,400	(15)
Cash collateral payables on derivative instruments		62,747	67,114	(7)
Financial liabilities designated at fair value		88,907	88,982	0
Due to customers		342,980	342,409	0
Accrued expenses and deferred income		5,648	6,850	(18)
Debt issued		133,291	140,617	(5)
Other liabilities	15, 16	60,023	61,692	(3)
<b>Total liabilities</b>		<b>1,308,280</b>	<b>1,361,309</b>	<b>(4)</b>
<b>Equity</b>				
Share capital		383	383	0
Share premium		34,079	34,614	(2)
Treasury shares		(750)	(1,160)	(35)
Equity classified as obligation to purchase own shares		(39)	(39)	0
Retained earnings		24,430	23,603	4
Cumulative net income recognized directly in equity, net of tax		(4,878)	(3,955)	23
<b>Equity attributable to UBS shareholders</b>		<b>53,226</b>	<b>53,447</b>	<b>0</b>
Equity attributable to non-controlling interests		4,331	4,406	(2)
<b>Total equity</b>		<b>57,557</b>	<b>57,852</b>	<b>(1)</b>
<b>Total liabilities and equity</b>		<b>1,365,837</b>	<b>1,419,162</b>	<b>(4)</b>

**PARTIES**

**OUR HEAD OFFICE**

**UBS AG**  
Bahnhofstrasse 45  
CH-8001 Zurich  
Switzerland

and

Aeschenvorstadt 1  
CH-4051 Basel  
Switzerland

**OUR OFFICE**

**UBS AG, London Branch**  
1 Finsbury Avenue  
London  
EC2M 2PP  
United Kingdom

**OUR PLACE OF BUSINESS IN HONG KONG**

52nd Floor  
Two International Finance Centre  
8 Finance Street  
Central  
Hong Kong

**SPONSOR**

**UBS Securities Asia Limited**  
52nd Floor  
Two International Finance Centre  
8 Finance Street  
Central  
Hong Kong

**AUDITORS**

**Ernst & Young Ltd**  
Aeschengraben 9  
P.O. Box 2149 CH-4002 Basel  
Switzerland

**LIQUIDITY PROVIDER**

**UBS Securities Hong Kong Limited**  
52nd Floor  
Two International Finance Centre  
8 Finance Street  
Central  
Hong Kong